Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale

Respiratory Medicine

Volumn 108, Issue 4, 2014, Pages 593-599

  Magnussen, Helgo ^a   Watz, Henrik ^a   Kirsten, Anne ^a   Decramer, Marc ^b   Dahl, Ronald ^c   Calverley, Peter M A ^d   Towse, Lesley ^e   Finnigan, Helen ^f   Tetzlaff, Kay ^g,h   Disse, Bernd ^g  

^a Member of the German Center for Lung Research   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e Boehringer Ingelheim   (United Kingdom)

^f Biometry and Data Management Department Boehringer Ingelheim (UK) Berkshire   (United Kingdom)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Chronic obstructive pulmonary disease; Dual bronchodilation; Exacerbation; Withdrawal of inhaled corticosteroid

Indexed keywords

ADIPONECTIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; FIBRINOGEN; FLUTICASONE; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; PLACEBO; PROCALCITONIN; SALMETEROL; SERUM AMYLOID A; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; BRONCHODILATING AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; BRONCHIECTASIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMPHYSEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENOTYPE; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; TREATMENT DURATION; TREATMENT WITHDRAWAL; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; TREATMENT OUTCOME; VITAL CAPACITY; WITHHOLDING TREATMENT;

EID: 84896066956     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.01.002     Document Type: Article

References (34)

1. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, and V. Aboyans et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
2. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2013 Updated 2013: http://www.goldcopd.org/uploads/users/files/GOLD- Report-2013-Feb20.pdf [accessed 15.07.13]
3. J.A. Wedzicha, M. Decramer, and T.A.R. Seemungal The role of bronchodilator treatment in the prevention of exacerbations of COPD Eur Respir J 40 2012 1545 1554
4. E.D. Bateman, G.T. Ferguson, N. Barnes, N. Gallagher, Y. Green, and M. Henley et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur Respir J 2013; May 30 [Epub ahead of print]
5. J.A. van Noord, J.-L. Aumann, E. Janssens, J.J. Smeets, J. Verhaert, and B. Disse et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD Eur Respir J 26 2005 214 222
6. J.A. Wedzicha, M. Decramer, J.H. Ficker, D.E. Niewoehner, T. Sandström, and A. Fowler Taylor et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Lancet Respir Med 1 2013 199 209
7. J. Vestbo, S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, and A. Anzueto et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
8. P. Lange, J.L. Marott, J. Vestbo, K.R. Olsen, T.S. Ingebrigtsen, and M. Dahl et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population Am J Respir Crit Care Med 186 2012 975 981
9. P.J. Barnes Inhaled corticosteroids in COPD: a controversy Respiration 80 2010 89 95
10. P.S. Burge, P.M.A. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, and T.K. Maslen et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial Br Med J 320 2000 1297 1303
11. C. Crim, P.M.A. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, and C. Jenkins et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Eur Respir J 34 2009 641 647
12. Ferguson GT. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH Trial. In: Abstract A763 presented at the 103rd Annual International Conference of the American Thoracic Society, San Francisco, California, USA, 18-23 May 2007.
13. R. Jen, S.I. Rennard, and D.D. Sin Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis Int J Chron Obstruct Pulmon Dis 7 2012 587 595
14. I.A. Yang, M.S. Clarke, E.H. Sim, and K.M. Fong Inhaled corticosteroids for stable chronic obstructive pulmonary disease Cochrane Database Syst Rev 7 2012 CD002991
15. E. Zervas, K. Samitas, M. Gaga, B. Beghe, and L.M. Fabbri Inhaled corticosteroids in COPD: pros and cons Curr Drug Targets 14 2013 224
16. J.A. Wedzicha, P.M.A. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
17. G.T. Ferguson, P.M.A. Calverley, J.A. Anderson, C.R. Jenkins, P.W. Jones, and L.R. Willits et al. Prevalence and progression of osteoporosis in patients with COPD. Results from the towards a revolution in COPD health study Chest 136 2009 1456 1465
18. D.D. Sin, D. Tashkin, X. Zhang, F. Radner, U. Sjöbring, and A. Thorén et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Lancet 374 2009 712 719
19. M.T. Dransfield, J. Bourbeau, P.W. Jones, N.A. Hanania, D.A. Mahler, and J. Vestbo et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials Lancet Respir Med 1 2013 210 223
20. J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerova, and R. Tal-Singer et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
21. A. Agusti, L.D. Edwards, S.I. Rennard, W. MacNee, R. Tal-Singer, and B.E. Miller et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype PLoS One 7 2012 e37483
22. L.E.G.W. Vanfleteren, M.A. Spruit, M. Groenen, S. Gaffron, V.P.M. van Empel, and P.L.B. Bruijnzeel et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 187 2013 728 735
23. A. Duvoix, J. Dickens, I. Haq, D. Mannino, B. Miller, and R. Tal-Singer et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease Thorax 68 2013 670 676
24. O. Holz, R.A. Jörres, S. Koschyk, P. Speckin, L. Welker, and H. Magnussen Changes in sputum composition during sputum induction in healthy and asthmatic subjects Clin Exp Allergy 28 1998 284 292
25. C. Cates Inhaled corticosteroids in COPD: quantifying risks and benefits Thorax 68 2013 499 500
26. N.J. Nadeem, S.J.C. Taylor, and S.M. Eldridge Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology Respir Res 12 2011 107
27. T.R.J. Schermer, A.J.C. Hendriks, N.H. Chavannes, P.N.R. Dekhuijzen, E.F.M. Wouters, and H. van den Hoogen et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice Prim Care Respir J 13 2004 48 55
28. E.F.M. Wouters, D.S. Postma, B. Fokkens, W.C.J. Hop, J. Prins, and A.F. Kuipers et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial Thorax 60 2005 480 487
29. A.B. Choudhury, C.M. Dawson, H.E. Kilvington, S. Eldridge, W.-Y. James, and J.A. Wedzicha et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial Respir Res 8 2007 93
30. P. van der Valk, E. Monninkhof, J. van der Palen, G. Zielhuis, and C. van Herwaarden Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study Am J Respir Crit Care Med 166 2002 1358 1363
31. S. Suissa, P. Ernst, K.L. Vandemheen, and S.D. Aaron Methodological issues in therapeutic trials of COPD Eur Respir J 31 2008 927 933
32. N.A. Jarad, J.A. Wedzicha, P.S. Burge, P.M.A. Calverley for the ISOLDE study group An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease Respir Med 93 1999 161 166
33. J.D. Leuppi, C.M. Salome, C.R. Jenkins, S.D. Anderson, W. Xuan, and G.B. Marks et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids Am J Respir Crit Care Med 163 2001 406 412
34. S. Suissa, and P.J. Barnes Inhaled corticosteroids in COPD: the case against Eur Respir J 34 2009 13 16